IFNB1 and multiple sclerosis: The European Medicines Agency (EMA) approved fingolimod as a single agent disease modifying therapy in patients with unsatisfactory disease control despite treatment with a beta interferon or in treatment-naïve patients with rapidly evolving severe multiple sclerosis, providing a second-line treatment option in highly active RRMS.